Brilinta
AstraZeneca’s Brilinta combo reduces rate of disabling stroke or death in stroke patients, according to Phase 3 data
November 9, 2020Research and Development, Sales and Marketing AstraZeneca, Brilinta, pharma
AstraZeneca has unveiled new Phase 3 data for Brilinta (ticagrelor) as a treatment for patients who have suffered an acute …
AstraZeneca presents strong Phase 3 Brilinta data for reducing CV risk
September 2, 2019Research and Development, Sales and Marketing AstraZeneca, Brilinta, pharma
AstraZeneca has unveiled new positive Phase 3 data on the efficacy of Brilinta (ticagrelor) in combination with aspirin, showing that …
AstraZeneca’s Brilinta proves safety in heart attack patients at Phase 3
March 12, 2018Research and Development, Sales and Marketing AstraZeneca, Brilinta, heart attack
AstraZeneca has revealed new Phase 3 data on its direct-acting P2Y12 receptor antagonist Brilinta (ticagrelor) at the American College of …
AstraZeneca’s Brilinta protects against adverse cardiovascular events for up to 5 years, new data reveals
September 7, 2017Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, pharma, pharmaceutical, ticagrelor, trial
AstraZeneca has revealed new data supporting the long-term use and efficacy of its cardiovascular drug Brilinta (ticagrelor), showing that the …
Extended use of AstraZeneca’s Brilinta reduces cardiovascular death risk
August 24, 2017Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, life sciences, pharma, pharmaceutical
New data for AstraZeneca’s blood thinner Brilinta (ticagrelor) has shown that extended use of the drug can cut the risk …
AstraZeneca’s Brilinta fails to best aspirin in treating stroke patients
March 23, 2016Research and Development AstraZeneca, Brilinta, stroke
AstraZeneca has announced top-line results from the Phase III SOCRATES trial, confirming that twice-daily doses of its drug Brilinta (ticagrelor) failed …
AstraZeneca looks to oncology match-ups to boost sales
April 24, 2015Sales and Marketing AstraZeneca, Brilinta, Celgene, Innate, Juno, farxiga, ticagrelor
AstraZeneca posted a 1% increase in revenue in its first-quarter 2015 financials – and is investing the money to back …
Mixed results for AstraZeneca in high-profile Brilinta study
March 17, 2015Sales and Marketing American College of Cardiology, AstraZeneca, Brilinta, EMA, FDA, ticagrelor
Experts say AstraZeneca is at risk of ‘diminishing returns’ in the clinical advantages of its blood-thinning drug Brilinta, after it …
AstraZeneca looks for revenue boost via Actavis buy
February 6, 2015Sales and Marketing Actavis, AstraZeneca, Brilinta, Forxiga, diabetes, fourth quarter, q4
AstraZeneca recorded a dip in revenue in the last quarter of 2014 and is looking to ramp up its respiratory …
AstraZeneca’s troubled Brilinta gets welcome lift
January 14, 2015Sales and Marketing AstraZeneca, Brilinta, FDA, US Department of Justice, acute coronary syndrome, ticagrelor
AstraZeneca has reported positive primary endpoint results for its anti-clogging drug Brilinta to treat patients who have had a heart …
Mixed results for AZ’s troubled Brilinta
September 3, 2014Sales and Marketing AstraZeneca, Brilinta, EMA, PCI, atlantic, heart, stent
The latest trial for AstraZeneca’s heart drug Brilinta (ticagrelor) has failed to meet expected results but suggests more flexible applications …
Reprieve for AstraZeneca as US drops drug investigation
August 19, 2014Sales and Marketing AstraZeneca, Brilinta, US, blood, justice, plato
The US Justice Department has pulled a controversial investigation into AstraZeneca’s pivotal clinical trial after finding no wrongdoing. The inquiry …
Profits slump at AstraZeneca
April 24, 2014Sales and Marketing AZD9291, AstraZeneca, BMS, Brilinta, Q1
AstraZeneca has continued its poor run of form, with operating profit in the first quarter of 2014 falling 40% on …
EMA questions Brilinta data
November 8, 2013Sales and Marketing Brilinta, EMA, astrazenca, heart, ticagrelor
The European Medicines Agency is demanding more information from AstraZeneca on its troubled heart pill Brilinta. This rounds off a …
AstraZeneca sees big sales drop in Q2
July 26, 2012Sales and Marketing AstraZeneca, Brennan, Brilinta, Q2, Seroquel
AstraZeneca has today reported a large drop in revenue for the second quarter. The firm has been hit by major …
Latest content
FibroFind appoints Lee Borthwick as CEO
